TET2 and leukemia: To further expand the understanding of acetylation mediated increase in TET2 activity, we treated TET2WT (CMK) and TET2MT (HEL and SIG-M5) leukemia cell lines with specific P300/CBP inhibitors C64640 or HATi41 and also with the sirtuin activator SRT172042 in the presence and absence of AA.